Article Details
Retrieved on: 2018-10-02 23:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Allogene debuted with $300 million in <b>first-round capital</b> and a suite of CAR-T assets licensed from Cellectis by way of Pfizer, and Belldegrun and ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here